BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shimbashi R, Suzuki M, Chang B, Watanabe H, Tanabe Y, Kuronuma K, Oshima K, Maruyama T, Takeda H, Kasahara K, Fujita J, Nishi J, Kubota T, Tanaka-Taya K, Matsui T, Sunagawa T, Oishi K; Adult IPD Study Group. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017. Emerg Infect Dis 2020;26:2378-86. [PMID: 32946721 DOI: 10.3201/eid2610.191531] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Tamura K, Chang B, Shimbashi R, Watanabe H, Tanabe Y, Kuronuma K, Oshima K, Maruyama T, Fujita J, Abe S, Kasahara K, Nishi J, Kubota T, Kinjo Y, Fujikura H, Fukusumi M, Shimada T, Sunagawa T, Suzuki M, Yamamoto Y, Oishi K; Adult IPD Study Group. Dynamic changes in clinical characteristics and serotype distribution of invasive pneumococcal disease among adults in Japan after introduction of the pediatric 13-valent pneumococcal conjugate vaccine in 2013-2019. Vaccine 2022:S0264-410X(22)00502-3. [PMID: 35489986 DOI: 10.1016/j.vaccine.2022.04.062] [Reference Citation Analysis]
2 Chang B, Kinjo Y, Morita M, Tamura K, Watanabe H, Tanabe Y, Kuronuma K, Fujita J, Oshima K, Maruyama T, Abe S, Kasahara K, Nishi J, Kubota T, Ohnishi M, Suga S, Oishi K. Distribution and Variation of Serotypes and Pneumococcal Surface Protein A Clades of Streptococcus pneumoniae Strains Isolated From Adult Patients With Invasive Pneumococcal Disease in Japan. Front Cell Infect Microbiol 2021;11:617573. [PMID: 33869075 DOI: 10.3389/fcimb.2021.617573] [Reference Citation Analysis]
3 Feemster KA, Kim Y, Abe M, Johnson K, Sasaki S. Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Rev Vaccines 2022;:1-2. [PMID: 35172667 DOI: 10.1080/14760584.2022.2036127] [Reference Citation Analysis]
4 Chandler T, Furmanek S, Carrico R, Balcom D, Arnold F, Ramirez J. 23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae. Microorganisms 2022;10:560. [DOI: 10.3390/microorganisms10030560] [Reference Citation Analysis]
5 Niederman MS, Folaranmi T, Buchwald UK, Musey L, Cripps AW, Johnson KD. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev Vaccines 2021;20:243-56. [PMID: 33478306 DOI: 10.1080/14760584.2021.1880328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]